• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical touches Endosense for $331M

St. Jude Medical touches Endosense for $331M

August 19, 2013 By Brad Perriello

St. Jude Medical touches Endosense for $331M
St. Jude Medical touches Endosense for $331M

St. Jude Medical (NYSE:STJ) said it agreed to pay up to $331 million, including $170 million in up-front cash, for Swiss force-sensing catheter maker Endosense.

St. Paul, Minn.-based St. Jude said the deal also includes provisions for milestone payments worth another $161 million "contingent upon both the achievement and timing of a regulatory milestone," likely pre-market approval from the FDA.

Endosense’s TactiCath device is designed to sense the force being applied to heart muscle during cardiac ablation procedures. CEO Jan Keltjens told MassDevice.com last summer that Endosense is likely to be the 2nd player in the U.S. force-sensing catheter market after Johnson & Johnson’s BioSense Webster subsidiary – and ahead of St. Jude.

"Apart from the fact that we are pioneering force-sensing, which is sometimes underestimated, is the fact that we think that by the time we get to the market we’ll be only the 2nd approved device in the U.S. in this space," Keltjens told us. "For now it’s a 1-horse race, it’s Biosense Webster. And I think it’s going to be a little bit of a neck-to-neck race with St. Jude Medical, but I would not be surprised if we pulled ahead of them and that we are the 2nd approved device."

Endosense closed a $40 million Series C round in November of last year, after winning CE Mark approval in the European Union for its 3rd-generation TactiCath Quartz device in June. The 1st U.S. use of the TactiCath Quartz came in February 2013, as part of Endosense’s just-completed Toccastar trial aimed at backing its application for pre-market approval from the FDA.

Endosense, which had said it hopes to file for PMA approval during the 4th quarter, now expects to file for a a paroxysmal atrial fibrillation indication "before the end of the year," according to a press release.

St. Jude said it funded the acquisition using cash reserves held outside the U.S. "and expects to make any future payments using these same cash balances."

"The acquisition of Endosense further strengthens our industry-leading portfolio of products to treat patients with cardiac arrhythmias, and provides an opportunity to accelerate our market share capture in the $900 million global cardiac ablation catheter market," St. Jude’s cardiovascular & ablation technologies president Frank Callaghan said in prepared remarks. "This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well."

Back in May 2012 at the Heart Rhythm Society meeting in Boston, Keltjens downplayed the possibility of an acquisition, saying he believed Endosense had the horses to go it alone.

"One of my philosophies is you don’t sell companies. What you do as a management team is you build a company. You build a business, and then at some point the proposition may become so compelling that one of the big ones is trying to take you out," he said. "That could be theoretically Biosense Webster, because they want to lock up the segment. I’m not going to speculate on whether they want to do it or not."

Filed Under: Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Ablation, Cardiac Rhythm Management, Endosense SA, Minnesota, stjudemedical

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy